Gasotransmitters—nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S)—are endogenously produced gaseous signaling molecules that play critical roles in neuronal function, neuroinflammation, and cell survival. Dysregulation of gasotransmitter signaling contributes to tauopathy pathology, making this pathway an emerging therapeutic target for CBS/PSP.
| Gasotransmitter | Finding in Tauopathy | Therapeutic Implication |
|---|---|---|
| NO | nNOS uncoupling → peroxynitrite formation | NOS isoform-selective modulation |
| CO | Reduced HO-1 activity | CO-RMs for neuroprotection |
| H2S | CBS/CSE downregulation | H2S donors for restoration |
Nitric oxide is produced by three nitric oxide synthase (NOS) isoforms:
Rationale: Excessive nNOS activity produces peroxynitrite (ONOO⁻), which nitrates tau and promotes aggregation.
| Compound | Mechanism | Stage | Notes |
|---|---|---|---|
| NANT-3 | nNOS selective | Preclinical | BBB penetration concerns |
| 7-NI | nNOS inhibitor | Research | Non-selective |
| TRIM | nNOS-PDI inhibitor | Preclinical | Dual mechanism |
Rationale: eNOS-derived NO is neuroprotective through vasodilation and anti-inflammatory effects.
| Compound | Mechanism | Evidence |
|---|---|---|
| L-arginine | NO precursor | Mixed clinical evidence |
| Statins | eNOS upregulation | Observational |
| ACE inhibitors | eNOS activation | Preclinical |
Rationale: iNOS upregulation in tauopathy drives neuroinflammation.
| Compound | Mechanism | Stage |
|---|---|---|
| L-NIL | iNOS selective | Research |
| S-methylisothiourea | iNOS inhibitor | Preclinical |
| ONO-1714 | iNOS inhibitor | Phase 1 |
Rationale: Neutralize peroxynitrite formed from NO + superoxide.
| Compound | Mechanism | Evidence |
|---|---|---|
| Ebselen | GPx mimetic, ONOO⁻ scavenger | Phase 2 in PD |
| Tempol | SOD mimetic | Preclinical |
| MnTBAP | SOD mimetic, ONOO⁻ decomposer | Preclinical |
| FeTPPS | ONOO⁻ decomposer | Research |
CO is produced by heme oxygenase (HO) enzymes:
CORMs release controlled amounts of CO to achieve therapeutic effects without toxicity.
| Compound | CO Release Profile | Application | Status |
|---|---|---|---|
| CORM-2 | Slow release (Ru carbonyl) | Research | Preclinical |
| CORM-3 | Fast release (water-soluble) | Research | Preclinical |
| CORM-401 | Mitochondria-targeted | Preclinical | Preclinical |
| DI-1 | Light-activated | Research | Preclinical |
| ALF-186 | Slow CO release | Veterinary | Approved |
| Compound | Mechanism | Evidence |
|---|---|---|
| Hemin | HO-1 transcription | Approved (porphyria) |
| Curcumin | Nrf2 → HO-1 | Clinical |
| Sulforaphane | Nrf2 → HO-1 | Clinical |
| Resveratrol | HO-1 upregulation | Clinical |
H2S is produced by:
| Donor | Release Profile | Notes |
|---|---|---|
| NaHS | Fast release | Short half-life |
| GYY4137 | Slow, sustained | Water-soluble |
| AP39 | Mitochondria-targeted | High potency |
| AP123 | mitochondria-targeted | Research |
| A-419259 | Slow release | Research |
| Compound | Mechanism | Evidence Level |
|---|---|---|
| Sulforaphane | CBS upregulation | Clinical |
| Alpha-lipoic acid | Sulfur donor | Clinical |
| NAC | Cysteine source | Clinical |
| Vitamin B6 | CBS cofactor | Clinical |
| Magnesium | CBS cofactor | Clinical |
| Compound | Mechanism | Status |
|---|---|---|
| Sodium sulfite | H2S release | Research |
| SF100 | CBS activator | Preclinical |
| SG1002 | H2S donor | Phase 1 (CV) |
Combining gasotransmitters can achieve synergistic neuroprotection through complementary mechanisms:
| Combination | Synergy Mechanism | Therapeutic Goal |
|---|---|---|
| CO + H2S | Mitochondrial protection | Enhanced neuroprotection |
| NO + H2S | Nrf2 activation | Antioxidant response |
| CO + NO | Anti-inflammatory | Reduced neuroinflammation |
| H2S + eNOS | Vasoprotection | BBB preservation |
Before initiating gasotransmitter therapy:
Baseline:
Monitoring:
| Agent | Contraindication |
|---|---|
| H2S donors | Severe liver disease, sulfide intolerance |
| CORMs | Active infection, pregnancy |
| NOS inhibitors | Hypotension, liver dysfunction |
| L-arginine | Herpes virus (arginine promotes replication) |
| Current Medication | Interaction | Management |
|---|---|---|
| Levodopa | No significant interaction | Monitor BP |
| Rasagiline | No significant interaction | Avoid high-dose nitrates |
| Blood pressure meds | Additive hypotension | Monitor, adjust dose |
| Domain | Score | Rationale |
|---|---|---|
| Mechanistic Rationale | 8/10 | Strong preclinical data |
| Clinical Evidence | 4/10 | Limited clinical trials in tauopathy |
| Safety Profile | 7/10 | Generally well-tolerated |
| BBB Penetration | 6/10 | Variable by compound |
| Combination Potential | 8/10 | Synergistic mechanisms |
| Total | 33/60 | 55% |
Priority: Moderate - Consider after higher-priority therapies initiated
Recommended Initial Protocol:
Rationale: This patient has high priority on disease modification. Gasotransmitter therapy provides:
Expected Timeline:
Action Items: